Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Lennard Lee, academic clinical lecturer at the Department of Oncology was recognised as part of the InterAcademy Partnership Young Physician Leaders Programme 2022

Department of Oncology Lecturer, Dr Lennard Lee was nominated by The Academy of Medical Sciences for safeguarding cancer and immunocompromised patients during the coronavirus pandemic and innovations in cancer diagnostics.

As part of selection into this group, Lennard met other young physician leaders from across the world in Berlin in October 2022 to harnesses the expertise of the world’s leading scientific minds to advance sound policies, improve public health and promote excellence in science education. He also was given the opportunity to present at the World Health Summit in Berlin a “global pact to protect those with cancer and the immunocompromised”

 

I am thrilled to be given this accolade for the United Kingdom. We have done so much work in the UK to safeguard cancer patients, including work showing that it was safe to deliver chemotherapy during the pandemic. Oxford University has delivered the largest global studies into vaccine effectiveness for cancer patients through the UK COVID Cancer Programme. My work would not be possible without the training and support that I have received from the Department of Oncology, Oxford University Hospitals, and the Oxford University Clinical Academic Graduate School and I am immensely grateful for their support and training - Dr Lennard Lee

Lennard is a great candidate and an excellent example of young physician leadership. We are delighted in getting him to share his contribution and insights at this international event in 2022 - Dr Peter McGrath, awarding panel from the global InterAcademy Partnership

Read about the other 2022 award winners.

 

Similar Stories

Cancer patients remain at higher risk of severe COVID-19 disease despite third dose booster vaccine

A large population-level assessment reveals third dose COVID-19 vaccination is effective for most patients with cancer, but effectiveness is lower than in the general population, particularly in patients who have undergone recent chemotherapy and those with lymphoma.

Oxford Cancer researchers elected to the European Molecular Biology Organization

Congratulations to Ivan Ahel, Adrian Hill and Yang Shi on their election to the membership of the European Molecular Biology Organization (EMBO)

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.